CRISPR Therapeutics Q4 2022 Earnings Report
Key Takeaways
CRISPR Therapeutics reported its Q4 and full year 2022 financial results, highlighting the completion of regulatory submissions for exa-cel in Europe and ongoing clinical trials for CTX110 and CTX130. The company is also advancing its regenerative medicine and in vivo programs. While collaboration revenue was not material for the quarter, R&D expenses were $103.6 million. The company's cash position remains strong at $1,868.4 million.
Regulatory submissions for exagamglogene autotemcel (exa-cel) completed in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD).
U.S. rolling Biologics Licensing Application (BLA) submission on track for completion by end of Q1 2023.
Enrollment and dosing ongoing for CTX110 and CTX130, targeting CD19+ B-cell malignancies and CD70 for the treatment of T cell lymphomas, respectively.
Initiating Phase 1/2 clinical trials for next generation CAR T products, CTX112 and CTX131, targeting CD19+ B-cell malignancies and CD70+ solid tumors, respectively.
CRISPR Therapeutics
CRISPR Therapeutics
Forward Guidance
CRISPR Therapeutics expects to continue expanding its portfolio of transformative medicines and improving its editing and delivery platform throughout 2023. The company anticipates initiating clinical trials for CTX112 and CTX131 in the first half of 2023 and advancing its lead in vivo program, CTX310, into clinical trials this year.
Positive Outlook
- Advancing lead in vivo program, CTX310, into clinical trials this year.
- Initiating clinical trials for CTX112 in the first half of 2023.
- Initiating clinical trials for CTX131 this year.
- Advancing additional programs directed towards cardiovascular risk reduction into the clinic in the next 12-18 months.
- Completing the U.S. rolling Biologics Licensing Application (BLA) submission by the end of Q1 2023.